- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sonia T. Oskouei, PharmD: The Launch of Biosimilar Rituximab and Its Impact on Cancer Care
Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses the launch of the first rituximab biosimilar in the United States.
Transcript
Yeah, it's a good question. So the rituximab biosimilar is very exciting, to be launched, the first one is just launched. And I think it's going to have a significant impact in oncology care. But I'm not sure it's going to be immediate.
Part of that is really the 10% pricing strategy that they came out with. I think it's safe to say that most providers and health system perspectives are hoping and anticipating at least a 15% to 30% discount based off of the originator biologic, which is what we've seen pretty consistently with other biosimilars.
So the 10% is hard to gauge because what you have to think about from a health system perspective is there is a significant cost of change. So for any new therapeutic, when you evaluate a drug for a [pharmacy and therapeutics, P and T] committee, and it becomes approved, there's a whole downstream effect of how to make it implemented within the health system.
So that includes IT updates to order sets, procurement and storage considerations, administration considerations, and then of course, the finance piece of doing prior authorizations and making sure the products are covered. So there's a whole downstream effect that becomes the cost of change that needs to be considered.
I don't think the 10% is going to be received with excitement from the provider lens, but I think it's going be interesting to see when additional competitors come to the market in this space, what that impact will be.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
